A Novel Molecular Mechanism of Dual Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2010 Mar 12

PMID 20219933

Citations 25

Authors

Galina N Nikolenko

Krista A Delviks-Frankenberry

Vinay K Pathak

Affiliations

Soon will be listed here.

Abstract

Recently, mutations in the connection subdomain (CN) and RNase H domain of HIV-1 reverse transcriptase (RT) were observed to exhibit dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs). To elucidate the mechanism by which CN and RH mutations confer resistance to NNRTIs, we hypothesized that these mutations reduce RNase H cleavage and provide more time for the NNRTI to dissociate from the RT, resulting in the resumption of DNA synthesis and enhanced NNRTI resistance. We observed that the effect of the reduction in RNase H cleavage on NNRTI resistance is dependent upon the affinity of each NNRTI to the RT and further influenced by the presence of NNRTI-binding pocket (BP) mutants. D549N, Q475A, and Y501A mutants, which reduce RNase H cleavage, enhance resistance to nevirapine (NVP) and delavirdine (DLV), but not to efavirenz (EFV) and etravirine (ETR), consistent with their increase in affinity for RT. Combining the D549N mutant with NNRTI BP mutants further increases NNRTI resistance from 3- to 30-fold, supporting the role of NNRTI-RT affinity in our NNRTI resistance model. We also demonstrated that CNs from treatment-experienced patients, previously reported to enhance NRTI resistance, also reduce RNase H cleavage and enhance NNRTI resistance in the context of the patient RT pol domain or a wild-type pol domain. Together, these results confirm key predictions of our NNRTI resistance model and provide support for a unifying mechanism by which CN and RH mutations can exhibit dual NRTI and NNRTI resistance.

Citing Articles

Retroviral RNase H: Structure, mechanism, and inhibition.

Ilina T, Brosenitsch T, Sluis-Cremer N, Ishima R Enzymes. 2021; 50:227-247.

PMID: 34861939 PMC: 8994160. DOI: 10.1016/bs.enz.2021.07.007.

Analysis and Molecular Determinants of HIV RNase H Cleavage Specificity at the PPT/U3 Junction.

Alvarez M, Sapena-Ventura E, Luczkowiak J, Martin-Alonso S, Menendez-Arias L Viruses. 2021; 13(1).

PMID: 33477685 PMC: 7831940. DOI: 10.3390/v13010131.

Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.

Saladini F, Giannini A, Boccuto A, Vicenti I, Zazzi M J Clin Lab Anal. 2017; 32(1).

PMID: 28303602 PMC: 6816933. DOI: 10.1002/jcla.22206.

Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.

Guo W, Han J, Zhuang D, Liu S, Liu Y, Li L Virol J. 2015; 12:187.

PMID: 26578099 PMC: 4650308. DOI: 10.1186/s12985-015-0417-y.

Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.

Putz M, Dudas N, Isvoran A Int J Mol Sci. 2015; 16(8):19553-601.

PMID: 26295229 PMC: 4581313. DOI: 10.3390/ijms160819553.

References

Yee J, Miyanohara A, Laporte P, Bouic K, Burns J, Friedmann T . A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci U S A. 1994; 91(20):9564-8. PMC: 44853. DOI: 10.1073/pnas.91.20.9564. View

Gopalakrishnan V, Benkovic S . Effect of a thiobenzimidazolone derivative on DNA strand transfer catalyzed by HIV-1 reverse transcriptase. J Biol Chem. 1994; 269(6):4110-5. View

Palaniappan C, Fay P, Bambara R . Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase. J Biol Chem. 1995; 270(9):4861-9. DOI: 10.1074/jbc.270.9.4861. View

Spence R, Anderson K, Johnson K . HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry. 1996; 35(3):1054-63. DOI: 10.1021/bi952058+. View

Ghosh M, Jacques P, Rodgers D, Ottman M, Darlix J, Le Grice S . Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. Biochemistry. 1996; 35(26):8553-62. DOI: 10.1021/bi952773j. View

Fan N, Rank K, Slade D, Poppe S, Evans D, Kopta L . A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Biochemistry. 1996; 35(30):9737-45. DOI: 10.1021/bi9600308. View

Naldini L, Blomer U, Gage F, Trono D, Verma I . Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A. 1996; 93(21):11382-8. PMC: 38066. DOI: 10.1073/pnas.93.21.11382. View

Esnouf R, Ren J, Hopkins A, Ross C, Jones E, Stammers D . Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci U S A. 1997; 94(8):3984-9. PMC: 20554. DOI: 10.1073/pnas.94.8.3984. View

Palaniappan C, Wisniewski M, Jacques P, Le Grice S, Fay P, Bambara R . Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function. J Biol Chem. 1997; 272(17):11157-64. DOI: 10.1074/jbc.272.17.11157. View

10.

Maga G, Amacker M, Ruel N, Hubscher U, Spadari S . Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J Mol Biol. 1998; 274(5):738-47. DOI: 10.1006/jmbi.1997.1427. View

11.

Kemp S, Shi C, Bloor S, Harrigan P, Mellors J, Larder B . A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol. 1998; 72(6):5093-8. PMC: 110074. DOI: 10.1128/JVI.72.6.5093-5098.1998. View

12.

Gerondelis P, Archer R, Palaniappan C, Reichman R, Fay P, Bambara R . The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities. J Virol. 1999; 73(7):5803-13. PMC: 112641. DOI: 10.1128/JVI.73.7.5803-5813.1999. View

13.

Sluis-Cremer N, Temiz N, Bahar I . Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res. 2004; 2(4):323-32. PMC: 1298242. DOI: 10.2174/1570162043351093. View

14.

Paolucci S, Baldanti F, Maga G, Cancio R, Zazzi M, Zavattoni M . Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication. Antimicrob Agents Chemother. 2004; 48(12):4611-7. PMC: 529209. DOI: 10.1128/AAC.48.12.4611-4617.2004. View

15.

Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J . TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004; 48(12):4680-6. PMC: 529207. DOI: 10.1128/AAC.48.12.4680-4686.2004. View

16.

Shaw-Reid C, Feuston B, Munshi V, Getty K, Krueger J, Hazuda D . Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry. 2005; 44(5):1595-606. DOI: 10.1021/bi0486740. View

17.

Nikolenko G, Palmer S, Maldarelli F, Mellors J, Coffin J, Pathak V . Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A. 2005; 102(6):2093-8. PMC: 548555. DOI: 10.1073/pnas.0409823102. View

18.

Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D . TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005; 79(20):12773-82. PMC: 1235844. DOI: 10.1128/JVI.79.20.12773-12782.2005. View

19.

Wang J, Dykes C, Domaoal R, Koval C, Bambara R, Demeter L . The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in.... Virology. 2006; 348(2):462-74. PMC: 4484593. DOI: 10.1016/j.virol.2006.01.014. View

20.

Srivastava S, Sluis-Cremer N, Tachedjian G . Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target. Curr Pharm Des. 2006; 12(15):1879-94. DOI: 10.2174/138161206776873590. View